Hey @LazarusRy
While I haven’t looked into it in the UK, and I understand it is frustrating, I have looked extensively at such an action here in Australia. I think as a community we need to consider how we best approach this strategically so all patients benefit, as successful legal action could have massive benefits in terms of funding future research.
Unfortunately, at this point I’ve been told by multiple class action specialists that we would not have a strong enough case due to the lack of causal connection between drug and symptoms. Any good corporate lawyer, and trust me, Merck has plenty, will just obfuscate the issue as they have in previous cases and in the public domain. It would most likely end up in a stalemate like it was in the US and lead to a poor outcome which also weakens future prospects.
Personally I believe we would be better waiting until we have such research completed, and then we collectively pursue action in multiple jurisdictions. I know it is frustrating for now, but it’s a topic I’ve thought about extensively and at this point, it seems the most sensible option.
Feel free to reach out privately also.
Best,
Mitch